|
EP400NL expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.686800E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.573800E-01 |
| Normal-vs-Stage2 |
2.037800E-01 |
| Normal-vs-Stage3 |
7.632200E-02 |
| Normal-vs-Stage4 |
1.444960E-01 |
| Stage1-vs-Stage2 |
3.941000E-01 |
| Stage1-vs-Stage3 |
1.172760E-01 |
| Stage1-vs-Stage4 |
2.507200E-01 |
| Stage2-vs-Stage3 |
8.580600E-01 |
| Stage2-vs-Stage4 |
9.614800E-01 |
| Stage3-vs-Stage4 |
8.930400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.507000E-01 |
| Normal-vs-AfricanAmerican |
1.226070E-02 |
| Normal-vs-Asian |
8.527200E-01 |
| Caucasian-vs-AfricanAmerican |
2.681800E-02 |
| Caucasian-vs-Asian |
7.233600E-01 |
| AfricanAmerican-vs-Asian |
2.239500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.494200E-01 |
| Normal-vs-Female |
2.388200E-01 |
| Male-vs-Female |
5.759400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.287600E-01 |
| Normal-vs-Age(41-60Yrs) |
2.504800E-01 |
| Normal-vs-Age(61-80Yrs) |
3.797600E-02 |
| Normal-vs-Age(81-100Yrs) |
7.687600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.637600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.010000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.881600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.622000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.815400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.446600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.07189999951774E-07 |
| Classical-VS-Follicular |
1.102210E-02 |
| Classical-VS-Other |
5.582000E-01 |
| Classical-VS-Normal |
9.136000E-01 |
| Tall-VS-Follicular |
1.407010E-01 |
| Tall-VS-Other |
1.154230E-01 |
| Tall-VS-Normal |
2.354400E-04 |
| Follicular-VS-Other |
7.234800E-01 |
| Follicular-VS-Normal |
3.952100E-02 |
| Other-VS-Normal |
5.312600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.733800E-02 |
| Normal-vs-N1 |
4.701200E-01 |
| N0-vs-N1 |
1.069950E-02 |
|
|
